CRISPR Therapeutics CRSP Other Noncash Income (Expense)
Other Noncash Income (Expense) at other companies
Other financials
Where this comes from
Reported directly by CRISPR Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:OtherNoncashIncomeExpense.
The official record: CRISPR Therapeutics’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →
Ask your AI about CRISPR Therapeutics's other noncash income (expense).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is CRISPR Therapeutics's other noncash income (expense)?
- CRISPR Therapeutics (CRSP) reported other noncash income (expense) of -$8.8M in Q1 2026.
- How has CRISPR Therapeutics's other noncash income (expense) changed year-over-year?
- CRISPR Therapeutics's other noncash income (expense) decreased by 290.6% year-over-year, from -$2.25M to -$8.8M.
- What is the long-term trend for CRISPR Therapeutics's other noncash income (expense)?
- Over 4 years (2021 to 2025), CRISPR Therapeutics's other noncash income (expense) has grown at a 13.6% compound annual growth rate (CAGR), from -$14.11M to $23.53M.
- What does other noncash income (expense) mean?
- This captures miscellaneous non-cash adjustments to net income that do not fit into standard categories like depreciation or stock-based compensation. It includes items such as changes in fair value of certain liabilities or non-cash impairment charges.